Ginkgo Bioworks Stock (NYSE:DNA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$8.33

52W Range

$5.26 - $75.20

50D Avg

$8.87

200D Avg

$31.36

Market Cap

$464.61M

Avg Vol (3M)

$1.52M

Beta

1.10

Div Yield

-

DNA Company Profile


Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

1,218

IPO Date

Apr 19, 2021

Website

DNA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Product$28.95M$35.45M$23.04M
Service$78.97M$298.58M$177.81M
Foundry Revenue-$143.67M$112.99M

Fiscal year ends in Dec 23 | Currency in USD

DNA Financial Summary


Dec 23Dec 22Dec 21
Revenue$251.46M$477.71M$313.84M
Operating Income$-864.41M$-2.21B$-1.83B
Net Income$-892.87M$-2.11B$-1.84B
EBITDA$-864.41M$-2.18B$-1.88B
Basic EPS$-0.56$-1.25$-1.35
Diluted EPS$-0.56$-1.25$-1.35

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 08, 24 | 9:02 PM
Q1 24May 09, 24 | 12:00 AM
Q4 23Feb 29, 24 | 9:35 PM

Peer Comparison


TickerCompany
CWBRCohBar, Inc.
AVROAVROBIO, Inc.
OCEAOcean Biomedical, Inc.
HEPAHepion Pharmaceuticals, Inc.
ELEVElevation Oncology, Inc.
ENVBEnveric Biosciences, Inc.